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The use of a temporary portocaval shunt (TPCS) as well as the order of reperfusion (initial arterial reperfusion [IAR] versus 
initial portal reperfusion) in orthotopic liver transplantation (OLT) is controversial and, therefore, still under debate. The aim 
of this study was to evaluate outcome for the 4 possible combinations (temporary portocaval shunt with initial arterial reperfu-
sion [A+S+], temporary portocaval shunt with initial portal reperfusion, no temporary portocaval shunt with initial arterial 
reperfusion, and no temporary portocaval shunt with initial portal reperfusion) in a center-based cohort study, including liver 
transplantations (LTs) from both donation after brain death and donation after circulatory death (DCD) donors. The primary 
outcome was the perioperative transfusion of red blood cells (RBCs), and the secondary outcomes were operative time and 
patient and graft survival. Between January 2005 and May 2017, all first OLTs performed in our institution were included in 
the 4 groups mentioned. With IAR and TPCS, a significantly lower perioperative transfusion of RBCs was seen (P < 0.001) 
as well as a higher number of recipients without any transfusion of RBCs (P < 0.001). A multivariate analysis showed labora-
tory Model for End-Stage Liver Disease (MELD) score (P < 0.001) and IAR (P = 0.01) to be independent determinants of 
the transfusion of RBCs. When comparing all groups, no statistical difference was seen in operative time or in 1-year patient 
and graft survival rates despite more LTs with a liver from a DCD donor in the A+S+ group (P = 0.005). In conclusion, next 
to a lower laboratory MELD score, the use of IAR leads to a significantly lower need for perioperative blood transfusion. 
There was no significant interaction between IAR and TPCS. Furthermore, the use of a TPCS and/or IAR does not lead to 
increased operative time and is therefore a reasonable alternative surgical strategy.
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During orthotopic liver transplantation (OLT), 
clamping and sectioning of the portal vein (PV) from 
the native liver induces splanchnic venous conges-
tion, intestinal edema, bacterial translocation, and 
accumulation of noxious elements.(1,2) The use of a 
temporary portocaval shunt (TPCS) may prevent 
these complications by alleviating gut edema, reducing 
bleeding with reduction of portal venous pressure, and 
improving hemodynamic stability.(3)
After the introduction of TPCSs in 1993 by Tzakis 
et al.,(4) the evidence of its benefit has been contro-
versial. Several retrospective studies have shown better 
intraoperative hemodynamic parameters, a decrease in 
the incidence of reperfusion syndrome,(5,6) and bet-
ter graft survival(7) by using a TPCS. However, other 
studies(3,8) showed no effect of a TPCS on intraopera-
tive transfusion of red blood cells (RBCs). Therefore, 
potential advantages of the TPCS remain question-
able, and its use is still debated.(9-11)
Several older, small, prospective studies that were 
nonrandomized, randomized, and retrospective 
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investigated initial arterial reperfusion (IAR)(12-17) 
and showed controversial results on outcomes after 
liver transplantation (LT). Thus, the ideal sequence 
of reperfusion is an issue that is still debated. The 
increased demand for LT has led to the increased use of 
extended criteria donor livers, specifically from dona-
tion after circulatory death (DCD) donors.(18-20) In 
contrast to LT with donation after brain death (DBD) 
organs, DCD LT is known to have an increased risk 
for posttransplantation complications, especially early 
allograft dysfunction, acute kidney injury, and nonan-
astomotic biliary strictures.(21) Little is known about 
the effect of a TPCS or IAR in DCD LT.
The aim of this study was to evaluate perioperative 
blood loss, hepatic injury, operative time, and out-
comes for LT with or without TPCS and/or IAR in a 
retrospective center-based cohort study including both 
DBD and DCD LTs. This study has received approval 
by the institutional review committee.
Patients and Methods
Patients
Between January 2005 and May 2017, all LTs at 
the Leiden University Medical Center, Leiden, the 
Netherlands, were included in this study. Recipients 
who received a domino, split, or auxiliary LT or a re-
transplantation were excluded. Clinical information 
was obtained from a prospectively collected database. 
Covariates included donor demographics, recipient 
demographics, pretransplant information, intraopera-
tive data, and postoperative outcomes.
Laboratory Model for End-Stage Liver Disease 
(MELD) scores were included in the recipient analysis. 
If necessary, the original patient notes were reviewed 
for missing information. The Eurotransplant donor 
risk index (ET-DRI), simplified recipient risk index 
(sRRI), combined donor-recipient model (DRM), 
and balance of risk (BAR) scores were calculated as 
described previously.(22-24) The peak value of aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) during the first 7 days after transplantation was 
used as a marker of ischemia/reperfusion injury.(25)
DeFinitiOn OF PeriOPerative 
BlOOD lOss
Mild blood loss requiring transfusion may often be on-
going after surgery. Therefore, perioperative blood loss 
was defined as the need for transfusion of RBCs during 
the first 24 hours after the start of surgery. Moreover, 
Cell Saver (LivaNova, London, UK) volume and fresh 
frozen plasma (FFP) transfusion were also noted.
OPerative tecHniQUes OF 
reciPient sUrgerY
Briefly, the standard incision and exposure was followed 
by the dissection of the hepatoduodenal ligament and by 
liver mobilization. Since May 2010, a change in center 
protocol was incorporated, which consisted of the use of 
a TPCS prior to mobilization and removal of the native 
liver. The TPCS consisted of an end-to-side anastomosis 
of the PV to the inferior vena cava at the level of the renal 
veins. After insertion of the liver graft, a side-to-side caval 
anastomosis was performed. Shortly after the introduc-
tion of a TPCS, IAR was introduced. In the historic con-
trol group, the portal anastomosis was directly followed 
by portal reperfusion of the liver. Thereafter, arterial 
anastomosis and reperfusion followed. Since the change 
in protocol, the arterial anastomosis has been directly fol-
lowed by arterial reperfusion of the liver. Hereafter, portal 
anastomosis and reperfusion followed. Just before portal 
reconstruction, the TPCS was divided using a vas cular 
endo GIA stapling device (Medtronic, Minneapolis, 
MN), after which a standard end-to-end portal anasto-
mosis was performed. Finally, biliary reconstruction was 
performed, preferably with a duct-to-duct anastomosis.
vein; RBC, red blood cell; SD, standard deviation; SE, standard error; 
sRRI, simplif ied recipient risk index; TPCS, temporary portocaval 
shunt; WIT, warm ischemia time.
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statistical analYsis
Continuous variables were presented as mean and 
standard deviation (SD), or median (range) and SD, 
whereas categorical variables were presented as n (%). 
Categorical variables were compared with the Pearson’s 
chi-square test. Characteristics of the donor, trans-
plantation, and recipient were analyzed using 1-way 
analysis of variance. Perioperative blood loss and peak 
value of AST and ALT were analyzed by using the 
Kruskal-Wallis test. Patient and graft survival rates, 
noncensored for death, were analyzed by Kaplan-
Meier estimation with a log-rank test for differences.
MUltivariate analYsis
To analyze the influence of covariates on blood loss, a 
multivariate logistic regression was performed using 
donor, transplantation, and recipient covariates that 
were most likely to influence blood loss. A possible 
interaction between TPCS and IAR was also exam-
ined in a secondary model. The level of significance 
was set at 0.05. Statistical analyses were performed 
using SPSS, version 25.0 for Windows (SPSS Inc., 
Chicago, IL).
Results
In total, 365 patients received a LT between January 
2005 and May 2017. There were 60 recipients who 
were excluded due to receiving either a domino LT 
(n = 3), split-liver transplantation (n = 2), auxiliary 
LT (n = 11), or retransplantation (n = 44). The use 
of a TPCS and the order of reperfusion could not 
be traced in 2 patients, who were therefore excluded 
from further analysis. Of the 303 recipients included 
in the study, 156 (51%) received no temporary por-
tocaval shunt with initial portal reperfusion (A−S−); 
15 (5%) received no temporary portocaval shunt with 
initial arterial reperfusion (A+S−); 41 (14%) received 
temporary portocaval shunt with initial portal reper-
fusion (A−S+); and 91 (30%) received temporary por-
tocaval shunt with initial arterial reperfusion (A+S+).
taBle 1. Donor, transplantation, and recipient characteristics
A−S− (n = 156) A+S− (n = 15) A−S+ (n = 41) A+S+ (n = 91) P Value
Donor age, years 48 ± 15 46 ± 20 46 ± 15 45 ± 16 0.56
Recipient age, years 54 ± 10 48 ± 15 52 ± 14 55 ± 10 0.10
Recipient BMI, kg/m2 27 ± 5 26 ± 4 25 ± 4 26 ± 4 0.36
Medical history, % 0.16
Metabolic disease 4 0 7 4
Acute liver disease 5 0 10 9
Cholestatic liver disease 11 40 17 13
Alcoholic liver disease 19 13 5 18
Malignancy 32 20 46 36
Hepatitis B 2 0 2 2
Hepatitis C 4 0 0 4
Other cirrhosis 15 7 7 9
Other/unknown 8 20 6 6
DCD liver grafts, % 33 27 32 54 0.005
Portal hypertension, % 25 43 44 35 0.10
ET-DRI 1.81 ± 0.3 1.73 ± 0.4 1.70 ± 0.3 1.83 ± 0.3 0.18
sRRI 1.96 ± 0.6 1.80 ± 0.4 1.94 ± 0.7 2.08 ± 0.7 0.26
DRM 1.40 ± 0.1 1.35 ± 0.1 1.38 ± 0.1 1.42 ± 0.1 0.11
BAR score 5.983 ± 4.2 5.60 ± 4.1 7.02 ± 5.3 6.38 ± 4.7 0.42
Laboratory MELD 15 ± 8 15 ± 9 16 ± 11 16 ± 9 0.75
CIT, minutes 566 ± 124 552 ± 168 522 ± 108 540 ± 127 0.18
WIT, minutes 34 ± 8 42 ± 11 38 ± 14 39 ± 12 <0.001
Operative time, minutes 338 ± 82 355 ± 99 358 ± 93 322 ± 90 0.12
NOTE: Data are presented as mean ± SD. Bolded values are significant.
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DOnOr, transPlant, anD 
reciPient cHaracteristics
Tables 1-4 show the basic donor, transplantation, and 
recipient characteristics of all groups. The A+S+ group 
consisted of a significantly higher percentage of DCD 
LTs compared with the other groups (33% in the A−S− 
group versus 27% in the A+S− group versus 32% in the 
A−S+ group versus 54% in the A+S+ group; P = 0.005). 
The warm ischemia time was significantly shorter 
in the A−S− group compared with the other groups 
(34  ±  8 minutes in the A−S− group versus 42  ±  11 
minutes in the A+S− group versus 38 ± 14 minutes in 
the A−S+ group versus 39 ± 12 minutes in the A+S+ 
group; P < 0.001). Other donor, transplantation, and 
recipient characteristics did not significantly differ 
among the groups. Also, the mean operative time did 
not significantly differ among the groups (P = 0.12).
BlOOD lOss
Tables 3 and 4 show the hematological and coagulation 
parameters of all groups preoperatively and the num-
ber of packed RBCs, FFP, and Cell Saver fluid (mL) 
transfused during the first 24 hours from incision. The 
partial thromboplastin time (PTT) in the A−S− group 
was significantly shorter compared with the other groups 
(P = 0.04). Other preoperative hematological and coag-
ulation parameters did not differ between both groups. 
The median number of packed RBCs transfused in the 
A−S− group was 6 ± 7 units (range, 0-33 units) versus 
2 ± 6 units (range, 0-19 units) in the A+S− group, 5 ± 6 
units (range, 0-30 units) in the A−S+ group, and 2 ± 5 
units (range, 0-23 units) in the A+S+ group (P < 0.001; 
Fig. 1). When analyzing outcomes based on TPCS sta-
tus alone, the use of a TPCS showed a significantly lower 
median number of transfused RBCs compared with the 
group who did not receive a TPCS (3 versus 6 units; 
P < 0.001).
Of the recipients in the A+S+ group, 31% did not 
receive any RBCs perioperatively, versus 28% in the 
A−S+ group, 27% in the A+S− group, and 8% in the 
A−S− group (P < 0.001). The mean amount of FFP 
transfused as well as the mean volume of Cell Saver 
transfused did not differ among the groups.




















NOTE: Bolded values are significant.
taBle 3. Hematological, coagulation, and transfusion Parameters Before, During, and after surgery
A−S− (n = 156) A+S− (n = 15) A−S+ (n = 41) A+S+ (n = 91) P Value
INR before surgery 1.35 ± 0.41 1.39 ± 0.48 1.51 ± 0.60 1.40 ± 0.44 0.25
Platelet count before  
surgery, 109/L
110 ± 80 164 ± 118 123 ± 98 119 ± 82 0.12
PTT before surgery, seconds 18 ± 7 20 ± 7 21 ± 9 20 ± 7 0.04
Fibrinogen before surgery, g/L 2.9 ± 1.4 3.5 ± 1.5 3.7 ± 5.6 2.8 ± 1.4 0.15
FFP, units 9 ± 9 7 ± 9 10 ± 9 8 ± 9 0.45
Packed RBCs, units 6 ± 7 2 ± 6 5 ± 6 2 ± 5 <0.001
Cell Saver, mL* 1072 ± 1158 918 ± 1006 887 ± 949 1418 ± 1231 0.11
No packed RBCs used, % 8 27 28 31 <0.001
NOTE: Data are presented as mean or median ± SD. Bolded values are significant.
*Cell Saver values were missing for 99 recipients.
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POsttransPlantatiOn PeaK 
OF ast anD alt
Table 5 shows the median peak of AST and ALT 
during the first 7 days after transplantation. The me-
dian peak of AST and ALT for all groups did not sig-
nificantly differ (AST, P = 0.89; ALT, P = 0.92).
When analyzing only DCD LT, the median peak of 
AST and ALT also did not significantly differ for all 
groups (AST, P = 0.13; ALT, P = 0.31). Also, when 
performing a Kaplan-Meier analysis with log-rank 
testing on biliary complications, no significant differ-
ence was seen among all groups (P = 0.57) even though 
the A+S+ group consisted of significantly more DCD 
LTs (P = 0.005).
POstOPerative cOMPlicatiOns
When comparing postoperative complications, no sta-
tistical difference was seen in Clavien-Dindo compli-
cations that were of a grade ≥3 (P = 0.85; Table 6).
Patient anD graFt sUrvival
Figure 2 shows the 1-year patient survival. No sig-
nificant difference was found when comparing all of 
the groups. Figure 3 shows the 1-year graft survival 
noncensored for death. No significant difference was 
found in 1-year patient survival or in 1-year graft sur-
vival noncensored for death.
MUltivariate analYsis
When performing multivariate logistic regression of 
all covariates included, the laboratory MELD score 
(P  <  0.001) and IAR (P  =  0.01) were identified as 
individual determinants for increased transfusion of 
RBCs. Interestingly, TPCS did not show a signif-
icant difference (P  =  0.78). Furthermore, IAR and 
TPCS did not show a significant statistical interaction 
(P = 0.54; Table 7). All other potential determinants 
did not show a significant difference.
Discussion
This cohort study demonstrates that LT with IAR and 
TPCS was associated with less perioperative trans-
fusion of RBCs. Furthermore, multivariate analysis 
showed that laboratory MELD and IAR were individ-
ual determinants on the number of RBCs transfused.
To our knowledge, this study is the first to use multi-
variate analysis to determine individual determinants 
of perioperative transfusion of RBCs in LT. When 
performing univariate analysis, a significant benefi-
cial effect of IAR and TPCS on transfusion of RBCs 
during LT was shown (P < 0.001). However, multi-
variate analysis showed only laboratory MELD and 
IAR to be individual determinants of perioperative 
taBle 4. Post Hoc analysis for Packed cells transfused

















NOTE: Bolded values are significant.
Fig. 1. Boxplot showing the distribution of RBCs transfused 
perioperatively among the 4 groups. • = outliers, * = extreme outliers.
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transfusion of RBCs, whereas the interaction between 
IAR and TPCS was low (P = 0.54). The beneficial 
effect of a TPCS, by using univariate analysis, has 
been described before (Table 8).(7,26-28) These studies 
do not describe the order of reperfusion used during 
transplantation, although we assume that portal 
reperfusion was first. A meta-analysis performed by 
Pratschke et al. showed a significant beneficial effect 
of a TPCS on operative blood loss, but the I2 values 
indicated substantial heterogeneity among the stud-
ies (P < 0.05), which could bring a potential bias to 
the results.(29)
taBle 5. Peak of ast and alt During the First 7 Days after transplantation for the Whole Population as Well as for DcD 
lt separately
A−S− (n = 156) A+S− (n = 15) A−S+ (n = 41) A+S+ (n = 91) P Value
AST, U/L 1218 ± 2832 1332 ± 1556 1096 ± 2974 1126 ± 2573 0.89
ALT, U/L 775 ± 1863 742 ± 1285 688 ± 1804 777 ± 1713 0.92
DCD LT
AST, U/L 2199 ± 4017 3833 ± 1900 1161 ± 4663 1309 ± 2893 0.13
ALT, U/L 1525 ± 2326 2011 ± 2000 947 ± 2877 925 ± 1814 0.31
NOTE: Data are given as median ± SD.
taBle 6. clavien-Dindo complications grade ≥3
A−S− (n = 156) A+S− (n = 15) A−S+ (n = 41) A+S+ (n = 91) P Value
Clavien-Dindo  
classification grade
3a 18 (12) 2 (13) 4 (10) 10 (11)
3b 27 (17) 3 (20) 5 (12) 18 (20)
4a 8 (5) 0 (0) 4 (10) 8 (9)
4b 7 (4) 0 (0) 1 (2) 1 (1)
5 5 (3) 1 (7) 1 (2) 3 (3)
Total 65 (42) 6 (40) 15 (37) 40 (44) 0.85
NOTE: Data are given as n (%).
Fig. 2. The 1-year patient survival curve.
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Multivariate analysis showed IAR to be an individ-
ual determinant on perioperative blood loss in LT. A 
possible explanation for this could be that the hepatic 
artery accounts for less total liver perfusion. Therefore, 
IAR may lead to a more controlled reperfusion and less 
blood loss.
This study also demonstrates that the use of a TPCS 
and the order of reperfusion used in LT do not have a 
significant influence on 1-year patient survival nor on 
1-year graft survival. In general, DCD LT is associ-
ated with more complications and inferior outcomes 
compared with DBD LT.(23,30) Even though the A+S+ 
group consisted of significantly more DCD LTs, we 
did not see a significant difference in patient and graft 
survival rates among the groups. Because the compli-
cation rate is higher with DCD LT compared with 
DBD LT, this may indicate a beneficial effect of both 
the use of IAR and TPCS. This is a very interesting 
finding that needs further research, especially because 
>40% of LTs in the Netherlands are with a DCD liver.
The operative time between the patients with or 
without TPCS was almost identical. Creating a TPCS 
takes some extra time, but clearly these extra minutes 
are saved during the rest of the procedure. A possi-
ble explanation could be that the TPCS causes less 
venous congestion and resolves portal hypertension. 
This may make liver mobilization easier with less risk 
of blood loss, and because the liver hilum is fully tran-
sected, this may facilitate access to the dissection plane 
between the liver and the caval vein. Therefore, less 
time may be needed for hemostasis and explantation 
of the native liver. Furthermore, a better hemodynamic 
Fig. 3. The 1-year graft survival curve noncensored for death.
taBle 7. Multivariate analysis on Perioperative transfusion 
of rBcs
B SE P Value
TPCS (n = 303) −0.001 0.15 0.78
IAR (n = 303) −0.386 0.15 0.01
Donor sex (n = 303) 0.136 0.11 0.20
Recipient sex (n = 303) 0.026 0.12 0.85
Recipient diagnosis (n = 303) 0.006 0.03 0.45
Donor liver type, DBD/DCD (n = 303) 0.057 0.12 0.82
Organ-perfusing support before 
transplant (n = 303)
−0.487 0.24 0.10
Platelets before operation, 109/L 
(n = 301)
0.0 0.001 0.83
Fibrinogen before operation, g/L 
(n = 299)
−0.038 0.02 0.13
Recipient age, years (n = 303) 0.001 0.005 0.61
Recipient BMI, kg/m2 (n = 303) 0.0 0.012 0.92
Donor age, years (n = 303) −0.003 0.004 0.52
Laboratory MELD (n = 303) 0.034 0.007 <0.001
Donor last GGT, U/L (n = 300) 0.001 0.001 0.33
Hepatic vein pressure gradient, mm 
Hg (n = 256)
0.0 0.006 0.89
TPCS * IAR  0.54
NOTE: Bolded values are significant. R2  =  0.224 (adjusted 
R2 = 0.127).
*Statistical interaction.
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status during surgery due to less venous congestion 
may result in a more controlled situation. Since the 
introduction of the new protocol with IAR and TPCS, 
a significant increase in the number of recipients who 
did not receive any perioperative transfusion of RBCs 
was seen. This is in concordance with Figueras et al.,(3) 
who showed less decrease in cardiac output in the 
TPCS group (P =  0.05) as well as a greater diuretic 
output during the anhepatic phase (P = 0.005).
This study has some potential limitations. First, 
the nonrandomized character could bring a poten-
tial bias. Most controls were from the oldest cohort. 
However, some of the controls were from the most 
recent cohort, when the use of a TPCS and choice of 
reperfusion technique were according to the surgeon’s 
preference. With the introduction of a new opera-
tive protocol, a selection bias is possible because the 
technique was new for some surgeons, and therefore, 
some preferred to use the previous surgical technique 
with initial portal reperfusion and no TPCS. Also, 
because of the retrospective character of the study, it 
is possible that other small changes in protocol have 
occurred during the study period, even though to our 
knowledge this is not the case. The major changes in 
protocol were the use of a TPCS and IAR. All rele-
vant factors were included in the multivariate analy-
sis to correct for these.
In conclusion, next to a lower laboratory MELD 
score, the use of IAR leads to significantly less periop-
erative blood transfusion. There was no significant 
interaction between IAR and TPCS. Furthermore, the 
use of a TPCS and/or IAR does not lead to increased 
operative time and is therefore a reasonable alternative 
surgical strategy.
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